EMCDDA Case study 5 — Expanding HCV screening and hepatitis treatment and care for PWID to harm reduction centres

Medicine and Dentistry

• Harm Reduction 100%
• Infection 66%
• Biological Marker 33%
• Human Immunodeficiency Virus 33%
• High Risk Population 33%
• Hepatitis B Virus 33%
• Antiviral Therapy 33%
• Hepatitis Virus 33%
• Transient Elastography 33%
• Syphilis Serology 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Infection 100%
• HIV 50%
• Virus Hepatitis 50%
• Biological Marker 50%
• Antivirus Agent 50%
• Hepatitis B Virus 50%
• Syphilis 50%